Multisite Radiotherapy Combined With Tislelizumab for Metastatic Castration-Resistant Prostate Cancer With Second-Line and Above Therapy Failure: Study Protocol for an Open-Label, Single-Arm, Phase Ib/II Study

• Published in: Frontiers in oncology 2022-07, Vol.12, p.888707-888707
• Main Authors: Cheng, Ke, Wang, Yuqing, Chen, Ye, Zhu, Jingjie, Qi, Xiaohui, Wang, Yachen, Zou, Yanqiu, Lu, Qiuhan, Li, Zhiping
• Format: Article
• Language: English
• Subjects: combination therapy; metastatic castration-resistant prostate cancer (mCRPC); multisite radiotherapy; Oncology; PD-1 monoclonal antibodies; study protocol; tislelizumab
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2022.888707

BackgroundTislelizumab combined with radiotherapy as a salvage treatment for patients with end-stage metastatic castration-resistant prostate cancer (mCRPC) is not reported. This study aimed to describe a protocol to evaluate the safety and efficacy of multisite radiotherapy combined with tislelizumab as a salvage therapy for mCRPC in patients who had at least one second-line treatment failure. MethodsThe study included patients with mCRPC who had at least one lesion suitable for radiotherapy and failed androgen deprivation therapy (ADT), followed by at least one novel second-line endocrine therapy. All patients received tislelizumab monotherapy induction therapy for two cycles, then combined with multisite radiotherapy for one cycle, followed by tislelizumab maintenance therapy, until either disease progressed or the patient developed unacceptable toxicity. Radiation methods and lesions were individually selected according to the specified protocol. Primary endpoints included safety and objective response rate. Secondary endpoints included prostate-specific antigen (PSA) response rate, disease control rate, overall survival, radiographic progression-free survival (rPFS), and biochemical progression-free survival (bPFS). Furthermore, the exploratory endpoints included the identification of the predictive biomarkers and exploration of the correlation between biomarkers and the tumor response to the combined regimen. DiscussionThis study included three treatment stages to evaluate the efficacy of immunotherapy and the combination of immunotherapy and radiotherapy for patients with mCRPC who have had at least second-line treatment failure. Additionally, radiation-related and immune-related early and late toxicities were determined, respectively. Furthermore, the study also aimed to identify the predictive biomarkers associated with immunotherapy for treating mCRPC. Trial Registrationhttps://www.chictr.org.cn/showproj.aspx?proj=126359, identifier ChiCTR2100046212.